Cargando…

Clinical implications of PET/CT in prostate cancer management

Several imaging modalities exist for the investigation of prostate cancer (PCa). From ultrasound to computed tomography (CT) and magnetic resonance imaging (MRI), the role of imaging in detecting lesion foci, staging, and localizing disease after biochemical recurrence (BCR) is expanding. However, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rayn, Kareem N., Elnabawi, Youssef A., Sheth, Niki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212623/ https://www.ncbi.nlm.nih.gov/pubmed/30456187 http://dx.doi.org/10.21037/tau.2018.08.26

Ejemplares similares

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
por: Lenzo, Nat P., et al.
Publicado: (2018)

Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer
por: Schwarzenböck, S., et al.
Publicado: (2012)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

PET/CT in Prostate Cancer
por: Evangelista, Laura, et al.
Publicado: (2023)

Clinical use of PET/CT in thyroid cancer diagnosis and management
por: Sundram, FX
Publicado: (2006)

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective
por: Hoffman, Azik, et al.
Publicado: (2023)

How we read FCH-PET/CT for prostate cancer
por: Beauregard, Jean-Mathieu, et al.
Publicado: (2016)

PET/CT imaging in prostate cancer
por: Barwick, Tara
Publicado: (2015)

Clinical Indications of (11)C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse
por: Picchio, Maria, et al.
Publicado: (2012)

PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art
por: Razik, Abdul, et al.
Publicado: (2018)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

[(18)F]Fluciclovine PET/CT Improves the Clinical Management of Early Recurrence Prostate Cancer Patients
por: Nappi, Anna Giulia, et al.
Publicado: (2022)

Choline PET/CT in recurrent prostate cancer
por: Detti, Beatrice, et al.
Publicado: (2023)

Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer
por: Al-Ibraheem, Akram, et al.
Publicado: (2009)

Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer
por: Kallur, Kumaraswamy G, et al.
Publicado: (2017)

New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review)
por: Simon, Hélène, et al.
Publicado: (2023)

Role and Cost Effectiveness of PET/CT in Management of Patients with Cancer
por: Saif, Muhammad Wasif, et al.
Publicado: (2010)

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review
por: Lisney, Anna Rebecca, et al.
Publicado: (2022)

PET/CT and Conventional Imaging for the Assessment of Neuroendocrine Prostate Cancer: A Systematic Review
por: Dondi, Francesco, et al.
Publicado: (2023)

Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review
por: Skanjeti, Andrea, et al.
Publicado: (2011)

The prognostic value of PET and PET/CT in cervical cancer
por: Grigsby, Perry W.
Publicado: (2008)

Clinical Utility and Future Applications of PET/CT and PET/CMR in Cardiology
por: Pan, Jonathan A., et al.
Publicado: (2016)

Irreversible electroporation for prostate cancer using PSMA PET-CT
por: Shin, Dongho, et al.
Publicado: (2023)

PET/CT Imaging for Personalized Management of Infectious Diseases
por: Pijl, Jordy P., et al.
Publicado: (2021)

Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
por: Regula, Naresh, et al.
Publicado: (2022)

The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate-Resistant Prostate Cancer Patients (nmCRPCp): diagnostic performance and impact on management
por: Soliman, Moataz, et al.
Publicado: (2023)

Association of Nadir Prostate-specific Antigen >0.5 ng/mL after Dose-escalated External Beam Radiation with Prostate Cancer-specific Endpoints
por: Sheth, Niki, et al.
Publicado: (2018)

Clinical practice in prostate PET imaging
por: Huls, Sean J., et al.
Publicado: (2023)

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2018)

Clinical perspectives of PSMA PET/MRI for prostate cancer
por: Barbosa, Felipe de Galiza, et al.
Publicado: (2018)

The Role of PET/CT in Breast Cancer
por: Hadebe, Bawinile, et al.
Publicado: (2023)

Role of PET/CT in Oropharyngeal Cancers
por: Avery, Emily W., et al.
Publicado: (2023)

Influence of [(18)F]FDG-PET/CT on Clinical Management Decisions in Breast Cancer Patients—A PET/CT Registry Study
por: Werner, Sebastian, et al.
Publicado: (2023)

Meta-analysis of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and (68)Ga-PSMA PET/CT in diagnostic efficacy of prostate Cancer
por: Yu, Wenxiao, et al.
Publicado: (2023)

(18)F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review
por: Rais-Bahrami, Soroush, et al.
Publicado: (2021)

The clinical significance and management of lesion motion due to respiration during PET/CT scanning
por: Callahan, Jason, et al.
Publicado: (2011)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

Application of SPECT and PET / CT with computer-aided diagnosis in bone metastasis of prostate cancer: a review
por: Chen, Zhao, et al.
Publicado: (2022)

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1odatvtgasjdte84to01ro5g12